CL2013002542A1 - Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas. - Google Patents
Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas.Info
- Publication number
- CL2013002542A1 CL2013002542A1 CL2013002542A CL2013002542A CL2013002542A1 CL 2013002542 A1 CL2013002542 A1 CL 2013002542A1 CL 2013002542 A CL2013002542 A CL 2013002542A CL 2013002542 A CL2013002542 A CL 2013002542A CL 2013002542 A1 CL2013002542 A1 CL 2013002542A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- tachycardia
- prophylaxis
- asthma
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La solicitud 201302542 describe al uso de una composición farmacéutica en forma de polvo seco inhalable que comprende entre 10 y 500 µg de bromuro de glicopirronio, monohidrato de lactosa y estearato de magnesio, la cual sirve para preparar un medicamento útil como un agente destinado a reducir el ritmo cardiaco.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1103770.2A GB201103770D0 (en) | 2011-03-04 | 2011-03-04 | Novel use |
GBGB1202256.2A GB201202256D0 (en) | 2012-02-09 | 2012-02-09 | Novel use |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013002542A1 true CL2013002542A1 (es) | 2014-07-11 |
Family
ID=45841526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002542A CL2013002542A1 (es) | 2011-03-04 | 2013-09-04 | Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas. |
Country Status (20)
Country | Link |
---|---|
US (2) | US20140080890A1 (es) |
EP (1) | EP2680841B1 (es) |
JP (1) | JP6129081B2 (es) |
KR (1) | KR101853997B1 (es) |
CN (1) | CN103501781B (es) |
AR (1) | AR085616A1 (es) |
AU (1) | AU2012226608B2 (es) |
BR (1) | BR112013022523A2 (es) |
CA (1) | CA2828640C (es) |
CL (1) | CL2013002542A1 (es) |
EA (1) | EA025287B1 (es) |
ES (1) | ES2613754T3 (es) |
GE (1) | GEP201706640B (es) |
IL (1) | IL227972A (es) |
JO (1) | JO3510B1 (es) |
MD (1) | MD4369C1 (es) |
MX (1) | MX356025B (es) |
TW (1) | TWI536988B (es) |
WO (1) | WO2012120284A1 (es) |
ZA (1) | ZA201306130B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2435024B1 (en) | 2009-05-29 | 2016-07-06 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
AU2013100007B4 (en) * | 2013-01-04 | 2013-05-23 | Novartis Ag | System for treating chronic obstructive pulmonary disease |
AU2013100009B4 (en) * | 2013-01-04 | 2013-03-14 | Novartis Ag | Treatment of chronic obstructive pulmonary disease |
KR102391332B1 (ko) | 2013-03-15 | 2022-04-26 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
UA115958C2 (uk) * | 2014-09-09 | 2018-01-10 | Вектура Лімітед | Препарат, що містить глікопіролат, спосіб та пристрій |
BR112017009315A2 (pt) * | 2014-11-05 | 2017-12-19 | Glenmark Pharmaceuticals Ltd | composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios. |
CN108135851B (zh) | 2015-09-09 | 2022-03-15 | 维克多瑞有限公司 | 射流研磨方法 |
ES2870984T3 (es) * | 2016-05-25 | 2021-10-28 | Claudia Mattern | Conjunto de pieza bruta de plástico de dos piezas |
PT109445B (pt) * | 2016-06-08 | 2018-11-06 | Hovione Farm Sa | Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose |
EP3595631A1 (en) * | 2017-03-15 | 2020-01-22 | Vectura Limited | Method and formulation |
KR102669919B1 (ko) * | 2019-07-10 | 2024-05-28 | 한미약품 주식회사 | 흡입용 캡슐제 및 이의 제조방법 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
BE718438A (es) * | 1967-08-23 | 1968-12-31 | ||
NL8104929A (nl) * | 1980-11-12 | 1982-06-01 | Alza Corp | Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan. |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
WO1998000109A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,r)-glycopyrrolate |
GB9808470D0 (en) * | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
KR20000013487A (ko) * | 1998-08-10 | 2000-03-06 | 정주영 | 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물 |
EP1283036B2 (de) | 1998-11-13 | 2020-01-01 | Jagotec AG | Multidosis-Trockenpulverinhalator mit Pulverreservoir |
GB9826284D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
GB9826286D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
DE10136404A1 (de) * | 2001-07-26 | 2003-02-20 | Johannes Wohlrab | Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis |
CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
SI1718336T1 (sl) | 2004-02-06 | 2008-10-31 | Meda Pharma Gmbh & Co Kg | Nova kombinacija antiholinergika in beta mimetikov za zdravljenje respiratornih bolezni |
GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
US7923455B2 (en) | 2005-01-28 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
GB0703999D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
WO2010144628A2 (en) | 2009-06-09 | 2010-12-16 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
-
2012
- 2012-02-26 JO JOP/2012/0040A patent/JO3510B1/ar active
- 2012-03-02 TW TW101106929A patent/TWI536988B/zh active
- 2012-03-05 MX MX2013009838A patent/MX356025B/es active IP Right Grant
- 2012-03-05 BR BR112013022523A patent/BR112013022523A2/pt not_active Application Discontinuation
- 2012-03-05 AR ARP120100709A patent/AR085616A1/es unknown
- 2012-03-05 EP EP12709151.0A patent/EP2680841B1/en active Active
- 2012-03-05 MD MDA20130069A patent/MD4369C1/ro active IP Right Grant
- 2012-03-05 KR KR1020137025861A patent/KR101853997B1/ko active IP Right Grant
- 2012-03-05 CA CA2828640A patent/CA2828640C/en active Active
- 2012-03-05 CN CN201280021503.6A patent/CN103501781B/zh active Active
- 2012-03-05 ES ES12709151.0T patent/ES2613754T3/es active Active
- 2012-03-05 AU AU2012226608A patent/AU2012226608B2/en active Active
- 2012-03-05 JP JP2013557170A patent/JP6129081B2/ja active Active
- 2012-03-05 WO PCT/GB2012/050478 patent/WO2012120284A1/en active Application Filing
- 2012-03-05 GE GEAP201213251A patent/GEP201706640B/en unknown
- 2012-03-05 EA EA201391275A patent/EA025287B1/ru not_active IP Right Cessation
- 2012-03-05 US US14/002,466 patent/US20140080890A1/en not_active Abandoned
-
2013
- 2013-08-15 IL IL227972A patent/IL227972A/en active IP Right Grant
- 2013-08-15 ZA ZA2013/06130A patent/ZA201306130B/en unknown
- 2013-09-04 CL CL2013002542A patent/CL2013002542A1/es unknown
-
2016
- 2016-01-31 US US15/011,582 patent/US10695321B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013002542A1 (es) | Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas. | |
PH12016501439B1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
BR112015012197A2 (pt) | terapia de combinação | |
MY183969A (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
BR112014016085A8 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
PE20141048A1 (es) | Combinacion que comprende umeclidinio y un corticosteroide | |
BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
PE20150171A1 (es) | Nueva forma de dosificacion y formulacion de abediterol | |
BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
PE20121467A1 (es) | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica | |
BR112017020039A2 (pt) | composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica | |
PE20070828A1 (es) | Composicion farmaceutica que contiene una sal de glicopirronio | |
MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
PE20141012A1 (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion | |
BR112012004692B8 (pt) | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano | |
AR100368A1 (es) | Tratamiento de trastornos respiratorios | |
AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
AR100784A1 (es) | Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador | |
AR085998A1 (es) | Aclidinio y su uso en la mejora de la calidad del sueño | |
BR112012023877A2 (pt) | dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal |